

Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than April 14, 2004. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous 1975 notice at 40 FR 43745-46 (September 23, 1975), all applicants for registration to import basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: March 5, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-5779 Filed 3-12-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 20, 2004, Lin Zhi International, Inc., 687 North Pastoria Avenue, Sunnyvale, California 94085, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

| Drug                                       | Schedule |
|--|----------|
| Tetrahydrocannabinols (7370) .....         | I        |
| 3,4-Methylenedioxyamphetamine (7405) ..... | I        |
| Amphetamine (1100) .....                   | II       |
| Methamphetamine (1105) .....               | II       |
| Secobarbital (2315) .....                  | II       |
| Phencyclidine (7471) .....                 | II       |
| Cocaine (9041) .....                       | II       |
| Benzoyllecgonine (9180) .....              | II       |
| Methadone (9250) .....                     | II       |
| Dextropropoxyphene (9273) .....            | II       |
| Morphine (9300) .....                      | II       |

The firm plans to manufacture small quantities of controlled substances to make drug testing reagents and controls. Any other such applicant and any person who is presently registered with DEA to manufacture such substance

may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than May 14, 2004.

Dated: March 5, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-5778 Filed 3-12-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 5, 2004, Mallinckrodt Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed below.

| Drug                                | Schedule |
|-------------------------------------|----------|
| Tetrahydrocannabinols (7370) .....  | I        |
| Codeine-N-oxide (9053) .....        | I        |
| Dihydromorphine (9145) .....        | I        |
| Difenoxin (9168) .....              | I        |
| Heroin (9200) .....                 | I        |
| Morphine-N-oxide (9307) .....       | I        |
| Nicomorphine (9312) .....           | I        |
| Normorphine (9313) .....            | I        |
| Norlevorphanol (9634) .....         | I        |
| Amphetamine (1100) .....            | II       |
| Methamphetamine (1105) .....        | II       |
| Methylphenidate (1724) .....        | II       |
| Codeine (9050) .....                | II       |
| Diprenorphine (9058) .....          | II       |
| Etorphine HCL (9059) .....          | II       |
| Dihydrocodeine (9120) .....         | II       |
| Hydromorphone (9150) .....          | II       |
| Oxycodone (9143) .....              | II       |
| Diphenoxylate (9170) .....          | II       |
| Benzoyllecgonine (9180) .....       | II       |
| Hydrocodone (9193) .....            | II       |
| Levorphanol (9220) .....            | II       |
| Meperidine (9230) .....             | II       |
| Methadone (9250) .....              | II       |
| Methadone Intermediate (9254) ..... | II       |
| Metopon (9260) .....                | II       |
| Dextropropoxyphene (9273) .....     | II       |
| Morphine (9300) .....               | II       |
| Thebaine (9333) .....               | II       |
| Opium extracts (9610) .....         | II       |
| Opium fluid extract (9620) .....    | II       |
| Opium tincture (9630) .....         | II       |

| Drug                               | Schedule |
|------------------------------------|----------|
| Opium, powdered (9639) .....       | II       |
| Opium, granulated (9640) .....     | II       |
| Levo-alphaacetylmethadol (9648) .. | II       |
| Oxymorphone (9652) .....           | II       |
| Alfentanil (9737) .....            | II       |
| Sufentanil (9740) .....            | II       |
| Fentanyl (9801) .....              | II       |

The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than May 14, 2004.

Dated: March 5, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-5773 Filed 3-12-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importation of Controlled Substances; Notice of Application**

Pursuant to section 1008 of the Controlled Substances Import and Export Act (21 U.S.C. 958(1)), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in Schedule I or II and prior to issuing a registration under section 1002(a) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with section 1301.34 of Title 21, Code of Federal Regulations (CFR), notice is hereby given that on January 6, 2004, Mallinckrodt Inc., Mallinckrodt & Second Streets, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration to be registered as an importer of the basic classes of controlled substances listed below:

| Drug                               | Schedule |
|------------------------------------|----------|
| Phenylacetone (8501) .....         | II       |
| Coca Leaves (9040) .....           | II       |
| Raw Opium (9600) .....             | II       |
| Opium poppy (9650) .....           | II       |
| Concentrate of Poppy Straw (9670). | II       |

The firm plans to import the listed controlled substances to bulk manufacture controlled substances.

Any manufacturer holding, or applying for, registration as a bulk manufacturer of the basic classes of controlled substances may file written comments on or objections to the application described above and may, at the same time, file a written request for a hearing on such application in accordance with 21 CFR 1301.43 in such form as prescribed by 21 CFR 1316.47.

Any such comments, objections, or requests for a hearing may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than April 14, 2004. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous 1975 notice at 40 FR 43745-46 (September 23, 1975), all applicants for registration to import basic class of any controlled substance in Schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1311.42(a), (b), (c), (d), (e), and (f) are satisfied.

Dated: March 5, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-5775 Filed 3-12-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Registration**

By Notice dated November 14, 2003, and published in the **Federal Register** on December 2, 2003, (68 FR 67477),

National Center for Development of Natural Products, The University, Mississippi, 135 Coy Waller Lab Complex, University of Mississippi 38677, made application by renewal to the Drug Enforcement Administration for registration as a bulk manufacturer of the basic classes of controlled substances listed below:

| Drug                               | Schedule |
|------------------------------------|----------|
| Marihuana (7360) .....             | I        |
| Tetrahydrocannabinols (7370) ..... | I        |

The firm plans to bulk manufacture for product development.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, section 823(a) and determined that the registration of National Center for Development of Natural Products, the University of Mississippi, to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated National Center for Development of Natural Products, The University of Mississippi, to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic classes of controlled substances listed is granted.

Dated: March 5, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-5772 Filed 3-12-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 29, 2004, Rhodes Technologies, 498 Washington Street, Coventry, Rhodes Island 02816, made application by renewal to the Drug Enforcement Administration (DEA) for registration as

a bulk manufacturer of the basic classes of controlled substances listed below.

| Drug                               | Schedule |
|------------------------------------|----------|
| Tetrahydrocannabinols (7370) ..... | I        |
| Methylphenidate (1724) .....       | II       |
| Codeine (9050) .....               | II       |
| Dihydrocodeine (9120) .....        | II       |
| Oxycodone (9143) .....             | II       |
| Hydromorphone (9150) .....         | II       |
| Hydrocodone (9193) .....           | II       |
| Thebaine (9333) .....              | II       |
| Noroxymorphone (9668) .....        | II       |
| Fentanyl (9801) .....              | II       |

The firm plans to produce bulk products for conversion and distribution to its customers.

Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration.

Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, United States Department of Justice, Washington, DC 20537, Attention: Federal Register Representative, Office of Chief Counsel (CCD) and must be filed no later than May 14, 2004.

Dated: March 5, 2004.

**William J. Walker,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 04-5781 Filed 3-12-04; 8:45 am]

**BILLING CODE 4410-09-M**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Manufacturer of Controlled Substances; Notice of Application**

Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on January 6, 2004, Roche Diagnostics Corporation, Attn.: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made renewal by letter to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic class of controlled substances listed below:

| Drug                              | Schedule |
|-----------------------------------|----------|
| Lysergic Acid Diethylamide (7315) | I        |
| Tetrahydrocannabinol (7370) ..... | I        |
| Alphamethadol (9605) .....        | I        |
| Phencyclidine (7471) .....        | II       |
| Benzoylcegonine (9180) .....      | II       |
| Methadone (9250) .....            | II       |
| Morphine (9300) .....             | II       |